Considering the large upregulation of MuRF1 expression in patients with NEM2 and that nebulin mutations are the most common cause of NM [14], we tested whether inhibition of MuRF1 is a therapeutic option for NM. The gene discussed is ACTA1; the disease is nemaline myopathy.